Cariprazine (Reagila) not recommended for use within NHS Wales for treatment of schizophrenia in adults

The clinical and cost-effectiveness data presented in the submission were insufficient for AWMSG to recommend its use in the sub-population highlighted by the applicant company.

All Wales Medicines Strategy Group